Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
Shots:
- The companies reported the positive results from two studies (EV-201 and EV-103) evaluating Padcev as monothx. and in combination with Merck’s Keytruda in patients with LA or mUC who are not able to receive cisplatin CT respectively
- An updated analysis of EV-201 Cohort 2 showed that 51% achieved confirmed objective response with CR (22%)- mDOR (13.8mos.)- mPFS (6.7mos.); OS (16.1mos.) with a median follow up of 16mos. The FDA has granted PR to the supplemental application of Padcev based on these results
- EV-103 cohort A patients demonstrated a safety profile is consistent with previous findings- with no new safety signals observed. The data will be presented at ASCO2021
Ref: PRNewswire | Image: Astellas
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
